Ivermectin,a US food and drug administration approved anti parasitic agent,was found to inhibit severe acute respiratory syndrome coronavirus 2 ( Sars -cov-2) replication in vitro.a randomized, double blind, placebo controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-COV-2 patients. The trial included 72 hospitalized patients in Dhaka,Bangladesh, who are assigned to one of three groups :

Oral ivermectin in combination with doxycyclin

(12 mg ivermectin single dose and 200 mg doxycyclin on day 1, followed by 100 mg every 12 hour for the next 4 days)

Oral ivermectin alone

( 12 mg once daily for 5 days)

And placebo control group.

Clinical symptoms of fever,cough, and sore throat were comparable among Three groups.

Virological clearance was earlier in the 5 day ivermectin treatment arm when compared to the placebo Group ( 9.7days vs.12.7 days ; p= 0.02)

But this was not the case for the ivermectin + doxycyclin arm ( 11.5 days,p= 0.27) there were no severe adverse drug events recorded in the study.

A 5 day course of ivermectin was Found to be safe and effective in treating adult patients with mild covid 19.larger trial will be needed to confirm these preliminary findings